Stock Ratings / Health Care / EYE / insiders

STAA (38) WRBY (52) BLCO (42) RXST (35) ⌘ Pro Terminal →

National Vision Holdings Inc. (EYE) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$16.64 +7.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $16.84

National Vision Holdings Inc. (EYE) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $1.32B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $16.84 (+1.18%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 3.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY • 56.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EYE)Realized 20D OHLCV Swing Band: ±9.7%

Deterministic 5-Pillar Attribution (68/100 Composite)

🔍 WHY EYE SCORES 68/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+16/20 pts (24% of score)

FRED Regime × Technicals: 12% of 52W Range • RSI-14 at 45.6 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+15/20 pts (22% of score)

20D Institutional Volume Accumulation (±9.7% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality10/20 pts (-10 pt drag)

Capital intensity & 3% operating margin leave 10 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$16.68+4.5% Next Q

Q2 (-2Q)

Grade B$17.43+7.1% Next Q

Q3 (-1Q)

Grade B$18.67-10.9% Next Q

Current

Grade C+$16.64+1.8% Hist 90D α

Trajectory: B+ (76) → C+ (68)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the EYE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 68/100 (C+) score, EYE faces multiple-compression risk if 44.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 44x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($17.04) or 200D SMA ($21.34) invalidates the momentum regime and cuts Target Base ($17.39) toward Bear Floor ($13.56).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EYE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EYE Beats Next Quarter EPS Consensus (Jan 2, 2027) & Holds Above 200D SMA”

YES 68%NO 32%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

EYE Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (EYE)

No recent open-market Form 4 cluster sales or emergency dumps flagged on EYE. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (EYE Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EYE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.34%📐 HORIZONTAL RANGE

2026-10-30O $16.95H $16.96L $16.22C $16.64VOL 2.42M

RES: $23.89SUP: $14.92SMA50: $17.04SMA200: $21.34

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EYE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EYE Butterfly Map → + Track EYE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

33.2%/yr Implied 5Y Growth

vs. +9.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EYE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EYE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EYE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EYE)

Health Care Rank #109 of 1016 ⚔️ STAA vs EYE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EYE vs. STAA, WRBY, BLCO, RXST)

Industry: Ophthalmic Goods (8 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, National Vision Holdings Inc. (EYE) ranks #109 by composite RQD confidence (68/100, grade C+) and #325 by equity capitalization ($1.32B). Within this direct 5-issuer industry benchmark cohort, EYE leads on earnings valuation at 44.4x trailing P/E, while EYE leads on capital efficiency and profitability with 4.4% ROIC and — gross margin. EYE currently leads its immediate peer cohort in composite quantitative strength at 68/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EYE ACTIVE National Vision Holdings Inc.	C+	68/100	44.4x	—	4.4%	+7.63%	$1.32B	Benchmark Subject
STAA STAAR Surgical Company	D-	38/100	—	76.2%	-35.0%	+2.56%	$1.27B	/staa-vs-eye →
WRBY Warby Parker Inc.	D+	52/100	—	54.0%	-1.7%	+0.66%	$3.04B	/wrby-vs-eye →
BLCO Bausch + Lomb Corporation	D-	42/100	—	—	0.8%	0.00%	$7.29B	/blco-vs-eye →
RXST RxSight Inc.	D-	35/100	—	76.6%	-14.9%	+3.06%	$210.0M	/rxst-vs-eye →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-01-03 • CIK 0001710155

In its most recent audited fiscal period (FY2025, filed 2026-01-03), National Vision Holdings Inc. (EYE) reported GAAP revenue of $1.99B (+9.0% vs. FY2024 revenue of $1.82B , and +13.2% cumulative change since FY2023) , GAAP net income of $29.6M, operating cash flow of $146.3M, and free cash flow of $73.5M (+92.6% YoY). On the balance sheet, EYE closed FY2025 with $1.98B in total assets against $223.2M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-01-03	$1.99B	$29.6M	$146.3M	$73.5M	$1.98B	$223.2M
FY2024 (FY)	2024-12-28	$1.82B	-$28.5M	$133.6M	$38.1M	$2.01B	$239.1M
FY2023 (FY)	2023-12-30	$1.76B	-$65.9M	$173.0M	$173.0M	—	—

3. EYE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EYE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, National Vision Holdings Inc. (NASDAQ: EYE) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $16.64 (+7.63% 1D, market cap $1.32B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, EYE ranks #109 in composite RQD confidence.

How does EYE compare to STAA and WRBY in the Health Care sector?

Within the Health Care sector (Ophthalmic Goods), EYE carries a Roarable C+ (68/100 RQD), trailing P/E of 44.4x, gross margin of —, and ROIC of 4.4%. By comparison, STAA (STAAR Surgical Company) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.27B) and WRBY (Warby Parker Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -1.7%, cap $3.04B). Among the 5-stock peer group, EYE leads on earnings multiple (44.4x) while EYE leads on capital efficiency (4.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EYE?

Per EYE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-01-03, CIK 0001710155), National Vision Holdings Inc. generated $1.99B in revenue (+9.0% YoY), $29.6M in net income, and $73.5M in free cash flow against $1.98B in total assets and $223.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Priced at 44x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EYE trading relative to its 50-day, 200-day, and 52-week technical levels?

EYE last traded at $16.64 (+7.63% on volume of 2,477,415 shares), positioning the stock -2.35% below its 50-day simple moving average ($17.04) and -22.02% below its 200-day simple moving average ($21.34). Across its 52-week range of $14.75 to $30.02, EYE sits at the 12.4% percentile with a 14-day RSI of 45.6 (NEUTRAL RANGE) and an implied next-earnings move of ±9.7% ($15.03 to $18.25).

EYE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are EYE insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies EYE leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: EYE RQD Cockpit EYE 12M Forecast EYE Earnings & Move EYE Dividends & DRIP EYE Insiders & 13F EYE Whale Options EYE Profit Sankey EYE News & Why